Chemical Property of FILGRASTIM
Edit
Chemical Property:
- PSA：0.00000
- LogP:0.00000
- Storage Temp.:-70°C
- Purity/Quality:
-
98%,99%, *data from raw suppliers
Filgrastim *data from reagent suppliers
Safty Information:
- Pictogram(s):
- Hazard Codes:
- MSDS Files:
-
Useful:
-
Description
Filgrastim is a recombinant human granulocyte colony stimulating factor (G-CSF)
indicated as an adjunct to cancer chemotherapy for patients with non-myeloid
malignancies. It reduces the duration of chemotherapy-induced neutropenia by forcing
immature leucocytes to differentiate into neutrophils, thereby decreasing the incidence
and length of infections.Bone pain is the most significant side effect.Chugai
launched the second G-CSF, lenograstim, in December 1991. Other potential uses
include bone marrow transplants, myelodysplastic syndromes and febrilelchronic
neutropenia.
-
Uses
Antineutropenic; hematopoietic stimulant. Filgrastim is a human granulocyte colony stimulating factor (G-CSF) used to treat neutropenia.
-
Indications
Filgrastim (Neupogen) is a human recombinant granulocyte
colony–stimulating factor (rG-CSF) produced
using recombinant DNA technology. It acts on precursor
hematopoietic cells in the bone marrow by binding
to specific receptors that stimulate cellular proliferation
and differentiation into neutrophils. It also enhances
some neutrophil functions, including phagocytosis and
antibody-dependent killing.
-
Clinical Use
Filgrastim, G-CSF, Neupogen, stimulates the proliferation ofgranulocytes (especially neutrophils) by mobilizinghematopoietic stem cells in the bone marrow. The native protein is glycosylated.Filgrastim selectively stimulates proliferation and differentiationof neutrophil precursors in the bone marrow. Thisleads to the release of mature neutrophils into the circulationfrom the bone marrow. Filgrastim also affects mature neutrophilsby enhancing phagocytic activity, priming the cellularmetabolic pathways associated with the respiratoryburst, enhancing antibody-dependent killing, and increasingthe expression of some functions associated with cell surfaceantigens.In patients receiving chemotherapy with drugs such ascyclophosphamide, doxorubicin, and etoposide, the incidenceof neutropenia accompanied by fever is rather high.Administration of G-CSF reduces the time of neutrophilrecovery and duration of fever in adults with acute myelogenousleukemia. The number of infections, days thatantibiotics are required, and duration of hospitalization arealso reduced. Filgrastim is used to accelerate recovery of neutrophils
after chemotherapy, both to prevent infections
and to shorten the duration of neutropenia in patients
in whom infections have developed.
-
Drug interactions
Potentially hazardous interactions with other drugs
Cytotoxics: neutropenia possibly exacerbated with
capecitabine, fluorouracil and tegafur.
